Investigational Study of Delayed Release Metformin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is suspended. It plans to enroll 675 participants.
Also called NCT04854512
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 675 participants
- Sponsor
- Anji Pharma
- Registry
-
NCT04854512
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Brazil, Bulgaria, Canada, Czechia, Hungary, Poland, Spain
- Registry status
- Suspended
Technical summary
Registry record NCT04854512. Randomized; double masking; primary purpose treatment. Start 2021-05-18 (actual); primary completion 2023-12-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Investigational Study of Delayed Release Metformin
- Acronym
- DREAM-T2D
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Metformin DR
- Intervention (Drug)
- Metformin IR
- Intervention (Drug)
- Metformin DR Placebo
- Intervention (Drug)
- Metformin IR placebo
- Lead sponsor
- Anji Pharma
Record details
- Record id
cardio:ct-nct04854512- Content hash
efbc125bf2dfbebefadd1b1bedccecc4bd7d39b9828b46a01b2c407ceff20eb5